G8, CARG, Frailty, and Nutritional Markers in Predicting Chemotoxicity

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

150 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-01-02

Study Completion Date

2026-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aims to evaluate the ability of G8, CARG, and Frailty scales to predict chemotherapy-related toxicity and the need for G-CSF in elderly cancer patients. It also investigates their correlation with nutritional biomarkers (albumin, prealbumin, hemoglobin, CRP) and the Mini Nutritional Assessment (MNA) test.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Nutrition Assessment in Advanced Cancer Patients

NCT06323135

Advanced Cancer Nutrition Aspect of Cancer Prognostic Cancer Model

COMPLETED

Analysis of Nutrition During Chemoradiotherapy in Patients With Gastrointestinal Cancer

NCT03286348

Nutritional Status Gastrointestinal Cancer Chemoradiotherapy

UNKNOWN

Temporal Transformation Mechanism and Intervention Strategies of Frail-related Dietary Behaviors in Older Gastric Cancer Survivors

NCT07176455

Gastric Cancer (GC) Frailty in Adult Surgery

ENROLLING_BY_INVITATION

Nutritional Risk Screening Nutritional Support Gastrointestinal Cancer

NCT06018246

Gastrointestinal Cancer

COMPLETED NA

Chemotherapy-related Toxicity, Nutritional Status and Quality of Life

NCT02848807

Toxicity Due to Chemotherapy Cancer Cachexia Metastatic Colorectal Cancer +2 more

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Background: Aging is associated with decreased physiological reserves, making elderly cancer patients more vulnerable to chemotherapy toxicity (CT). Traditional performance scales like ECOG may be insufficient for treatment decisions. Tools such as G8, Clinical Frailty Scale (CFS), and the Cancer and Aging Research Group (CARG) score are practical screening instruments recommended by ASCO and SIOG, yet their combined predictive accuracy for CT and granulocyte colony-stimulating factor (G-CSF) usage remains underexplored.

Objectives: This prospective study aims to evaluate the predictive performance of the G8, CARG, and Frailty scales-alone and in combination with nutritional biomarkers (albumin, prealbumin, hemoglobin, CRP)-in forecasting chemotherapy-related toxicity and G-CSF need. It also investigates the correlation between these geriatric assessment tools and Mini Nutritional Assessment (MNA) scores.

Methods: The study will be conducted at Çanakkale University Medical Faculty Oncology Outpatient Clinic. Patients aged 65 and above with a planned chemotherapy regimen will be recruited. Before the first chemotherapy cycle, patients will undergo G8, CARG, Frailty, and MNA assessments. Nutritional biomarkers will be extracted from pre-treatment routine lab tests. Chemotherapy toxicity and G-CSF requirement will be monitored across treatment cycles. ROC, correlation, and regression analyses will be conducted to evaluate predictive validity.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Geriatric Oncology Oncology Nutrition Nutrition Assessment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

The study group consists of cancer patients aged 65 and older who are scheduled to receive at least two cycles of chemotherapy. Patients with hematological malignancies or receiving concurrent targeted, hormonal, immunotherapy, or radiotherapy are excluded.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 65 years
* Diagnosed with solid tumor malignancy
* Planned to undergo at least two cycles of adjuvant, neoadjuvant, or metastatic chemotherapy
* Clinically stable condition
* Provided written informed consent

Exclusion Criteria

* Presence of hematological malignancies
* Concurrent hormonal therapy, targeted therapy, immunotherapy, or radiotherapy
* Acute infection or advanced organ failure (cardiac, hepatic, renal)
* Cognitive or psychiatric impairment preventing test participation
* Prior treatment with G-CSF

Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No